Navigation Links
First treatment for muscular dystrophy in sight: Scientists successfully harness exon-skipping
Date:3/16/2009

WASHINGTON, DCGenetic researchers at Children's National Medical Center and the National Center of Neurology and Psychiatry in Tokyo published the results of the first successful application of "multiple exon-skipping" to curb the devastating effects of Duchenne muscular dystrophy in an animal larger than a mouse. Multiple exon-skipping employs multiple DNA-like molecules as a "DNA band-aids" to skip over the parts of the mutated gene that block the effective creation of proteins.

The study, conducted in Japan and the United States, published this month in the peer-reviewed journal of the American Neurological Association, the Annals of Neurology, treated dogs with naturally occurring canine X-linked muscular dystrophy, a disease which is genetically homologous to the Duchenne muscular dystrophy that strikes 1 of every 3,500 boys born in the United States and worldwide each year.

Duchenne muscular dystrophy, one of the most common lethal genetic disorders, is an X-linked genetic mutation that causes an inability of the body's cells to effectively create dystrophinwhich builds muscle tissue. "Exon-skipping" employs synthetic DNA-like molecules called antisense as a DNA band-aid to skip over the parts of the gene that block the effective creation of dystrophin. Because the gene's mutation could affect any of its 79 exons and sometimes more than one single exon at a time, scientists employed a "cocktail" of antisense called morpholinos to extend the range of this application. By skipping more than a single exon, this so-called DNA band-aid becomes applicable to between 80 and 90 percent of Duchenne muscular dystrophy patients, including the mutation found in dogs.

"This trial makes the much-talked about promise of exon-skipping as a systemic treatment for Duchenne muscular dystrophy in humans a real possibility in the near term," said Toshifumi Yokota, PhD, lead author of the study. "Of course this success has also introduced even more avenues for investigation, but these findings finally overcome a significant hurdle to our progresswe've solved the riddle of an effective system-wide delivery to muscle tissue, and seen promising results."

A new state-of-the-art facility at the National Center of Neurology and Psychiatry in Japan was utilized to carry out the research.

"This study delivers the proof-of-concept that systemic anti-sense therapy can be done in a large organism, in Duchenne muscular dystrophy or any disease", says Eric Hoffman, PhD, a senior author of the study and director of the Center for Genetic Medicine at Children's National Medical Center.

"Systemic treatment of the majority of Duchenne dystrophy will require multiple sequences to be delivered in the blood, and this study also is the first proof-of-principle of multiple exon-skipping in any organism," Shin'ichi Takeda, MD, another senior author, said. "In order to realize that promise in human trials, it also will be important to re-evaluate current measures of toxicity, efficacy, and marketing that ensure both safety for the patient, as well as rapid development and distribution of life-saving drugs.

The authors do note that significant steps still remain. Successful systemic treatment with morpholinos requires large doses of the antisense moleculesand the technology is costly and difficult to obtain. Additionally, treatment in this study showed diminished success at curbing muscle deterioration of the heart, meaning that a more effective and specific delivery system is needed to rescue the organ's delicate tissue in Duchenne muscular dystrophy patients. However, these early successes do show much promise for the oft-discussed exon-skipping method as an effective treatment for Duchenne muscular dystrophy and some other genetic disorders.


'/>"/>

Contact: Jennifer Leischer
jleische@cnmc.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Related medicine news :

1. Expresso Fitness(R) Launches First Virtual Reality Cardio Bike for Kids
2. ABMS Hosts First National Health Policy Forum to Address Physician Accountability and Health System Performance Standards
3. Young Onset Parkinson Conferences: A First-Ever Collaboration
4. First DHI-Licensed Door Inspection Software Solution Ships to DOORDATA Solutions' Charter Members
5. Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company
6. Beckman Coulter Announces First in Series of Flow Cytometry Product Introductions for 2009
7. First Rewards Paid to New Jersey Doctors Through Participation in Bridges to Excellence
8. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
9. BridgePoint Medical Completes First U.S. Clinical Case Using CrossBoss and Stingray Devices in CTO Angioplasty Procedure
10. Yankees Will Become First MLB Team to Integrate Highly Advanced Antimicrobial System
11. Cepheid Receives Health Canada License for First On-demand Diagnostic Test for Life-threatening MRSA and S. aureus Infections From Patient Positive Blood Culture Bottles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, ... Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals who have made a ... going above and beyond the standard of care, demonstrating leadership within the MPN community ...
(Date:12/2/2016)... ... 2016 , ... FlexiSpot, a trusted name in sit-stand solutions ... for all of the company’s desktop riser products. A simple application form and ... FlexiSpot’s unique desktop risers use an advanced dual gas spring hovering system to ...
(Date:12/2/2016)... ... 02, 2016 , ... With the number of pain management programs available for ... find the one that works for them. When an inventor from Suisun City, Calif., ... and decided to share it with others. , He developed a prototype for PRO ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... edition of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic ... health while maintaining fulfilling lives. “We are prolonging life 6 years in the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the 5,000 ... unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition to ... been available in several ShopRite and FoodTown stores in NJ and received rave comments ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... -- Maxor National Pharmacy Services, LLC ("Maxor"), today announced that it ... combination of Texas -based Maxor Specialty / ... together both company,s clinical expertise and high-touch patient service models ... pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... WOONSOCKET, R.I. , Dec. 2, 2016 ... hold its annual Analyst Day in New York City on Thursday, December ... the CVS Health leadership team will provide an in-depth ... and enhance shareholder value. The company will also discuss ... audio and video webcast of the event will be ...
(Date:12/2/2016)... 2, 2016 Orthopedic Implants (Including Spinal ... Expected to Gain a Significant Market Share Owing to a ... ... According to a new report by ... Sterile Packaging: Clamshell Product Type Segment Projected to Witness a ...
Breaking Medicine Technology: